国内临床CRO龙头企业泰格医药(300347.SZ)于12月15日起正式被调出深证100成份股,结束了自2019年12月纳入以来长达六年的指数生涯。此次调整正值CRO行业因“猴荒”再现迎来普涨行情,板块内多数企业股价上行。 然而,泰格医药走势却与行业背离,成为板块中唯一的“失意者”。 Wind数据显示,2025年以来,在CXO指数(931750.CS)与CRO指数(8841421.WI)29只...
Source Link国内临床CRO龙头企业泰格医药(300347.SZ)于12月15日起正式被调出深证100成份股,结束了自2019年12月纳入以来长达六年的指数生涯。此次调整正值CRO行业因“猴荒”再现迎来普涨行情,板块内多数企业股价上行。 然而,泰格医药走势却与行业背离,成为板块中唯一的“失意者”。 Wind数据显示,2025年以来,在CXO指数(931750.CS)与CRO指数(8841421.WI)29只...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.